Clinical development of IDH1 inhibitors for cancer therapy

Since the validation of targeted cancer therapies in the late 1990s, numerous active agents have been developed against a variety of different cancer types. Rituximab and trastuzumab were among the first examples, which proved to be highly effective against B-cell lymphoma and HER2-positive breast cancer, respectively [1,2]. In the last seven years alone, 83 drugs aimed at 56 different targets have been approved by the United States Food& Drug Administration (FDA) for the treatment of solid and hematologic malignancies [3].

Source: Cancer Treatment Reviews - December 28, 2021 Category: Cancer & Oncology Authors: Mehrdad Zarei, Jonathan J. Hue, Omid Hajihassani, Hallie J. Graor, Erryk S. Katayama, Alexander W. Loftus, David Bajor, Luke D. Rothermel, Ali Vaziri-Gohar, Jordan M. Winter Source Type: research